A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Astellas

Status and phase: Completed; Phase 2

Conditions: Cancer of Prostate; Prostatic Cancer; Prostate Cancer; Cancer of the Prostate

Treatments: Drug: YM155

Study type: Interventional

Funder types: Industry

Identifiers

NCT00257478

155-CL-007

Details and patient eligibility

About

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed prostate cancer.
• Prior chemotherapy regimen for prostate cancer

Exclusion criteria

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)